Although others have also recently shown the superiority of dual EZH1/2 inhibitors such as VAL, the contribution of EZH1 to H3K27 methylation states in cancer and the mechanism behind this superiority remains unclear (24,25). The gene discussed is EZH1; the disease is cancer.